NAD+ Nasal Spray: What It Is, Where to Get It Prescribed, and What It Costs

The active ingredient is nicotinamide adenine dinucleotide in its oxidised form, the same molecule supplied in the NAD+ Injection. It is a coenzyme, not a peptide: two nucleotides joined through a pyrophosphate bridge, one carrying nicotinamide (a form of vitamin B3), the other adenine. Every cell makes it and consumes it constantly.

What differs is the door: a large dose into the fat layer three times a week, or a small dose onto the lining of the nose twice a day — and a much thinner evidence base for how much of it gets in.

Two reasons, best kept apart. The practical one: some people will not inject, and some who have injected NAD+ dislike the flushing and chest tightness that comes with it entering the circulation quickly. A spray removes the needle and the bolus.

The research one: the lining of the upper nose sits close to the olfactory and trigeminal nerves, and rodent studies of intranasal NAD+ after stroke and head injury, described below, are the origin of the interest. They are acute-injury models at doses far above what a spray delivers.

It is not a vitamin, although it is made from one. It is not NMN or NR, the oral precursors most of the human trial literature is about, so precursor results cannot be transferred to it. It is not an inhaler, a decongestant or a steroid spray. And it is not a treatment for any diagnosed condition, because it has no approved indication.

NAD+ collects electrons from the breakdown of glucose and fatty acids and hands them, as NADH, to the mitochondrial electron transport chain to make ATP. This is textbook metabolism, and why total NAD+ deficiency — pellagra — is a recognised disease treated with niacin.

Sirtuins remove acetyl groups from proteins and consume one NAD+ each time; PARP enzymes respond to DNA breaks by building ADP-ribose chains, each unit costing an NAD+. Both draw on the same pool, and a 2018 review in Cell Metabolism by Rajman, Chwalek and Sinclair set out the in vivo case — largely from animals — that keeping the pool topped up allows more repair and maintenance activity. That is a mechanism argument, untested as a human outcome with NAD+ itself. The age-related decline it rests on is observational — a 2012 study in PLOS ONE by Massudi and colleagues measured lower NAD+ in older human skin — and showing a decline is not showing that a spray changes it.

The nasal cavity has a large, well-supplied surface, which is why some drugs — certain hormones, migraine medicines, naloxone — work well as sprays. But the lining is built to clear what lands on it: mucus is swept backwards by cilia and swallowed, and nasal drug-delivery reviews describe a clearance half-time of around fifteen to twenty minutes for a liquid deposited in the nose. Whatever has not crossed by then goes down the throat.

Crossing depends on the molecule. Small, fat-soluble molecules pass easily; NAD+ is neither, at about 663 daltons and strongly negatively charged at physiological pH — the profile Illum's 2003 review in the Journal of Controlled Release lists among the difficult cases for nasal absorption without an enhancer. Whether a plain NAD+ solution crosses the human nasal lining in a meaningful amount has not been measured in a published study. It may. Nobody has shown it.

The second proposed route bypasses the bloodstream. Lochhead and Thorne's 2012 review in Advanced Drug Delivery Reviews sets out how molecules deposited on the olfactory region at the top of the nasal cavity, and along trigeminal branches, can reach the brain directly in animals, and in a smaller number of human studies of other compounds. The caveats: only the upper nose has olfactory lining, an ordinary spray deposits most of its volume lower down, and the rat nasal cavity has a far larger proportion of olfactory epithelium than the human one. A rodent result applied to a person spraying at home is a hypothesis, not a finding.

A 2007 paper in Frontiers in Bioscience by Ying and colleagues gave rats 10 mg/kg of NAD+ intranasally two hours after an induced stroke and reported higher brain NAD+ content, a smaller area of dead tissue and less neurological deficit; the same dose of nicotinamide did not help. A 2012 paper in the Journal of Neurotrauma by Won and colleagues gave rats 20 mg/kg intranasally immediately after a weight-drop head injury and reported protection of neurons in parts of the hippocampus, though not the cortex. A 2015 paper in Brain by Zhou and colleagues reported that intranasal NAD+ in prion-infected mice improved activity and delayed motor impairment. In each case the injury was draining NAD+ through PARP overactivation, and a large intranasal dose reached the brain and reduced the damage.

Three things separate them from this product. The dose: 10 to 20 mg per kilogram as a single rescue treatment is not comparable to 0.2 mL of a 12 mg/mL solution twice a day. The timing: they treated a catastrophic injury as it happened, nothing like daily use in an uninjured adult. And the species: rodent nasal anatomy favours nose-to-brain transfer far more than human anatomy does.

The randomised human trials used NMN or NR capsules, not NAD+ and not a spray, and matter only as the best evidence on what raising NAD+ in people does. Martens and colleagues, Nature Communications 2018, reported NR well tolerated in healthy middle-aged and older adults and raising NAD+ in blood cells. Dollerup and colleagues, American Journal of Clinical Nutrition 2018, found no metabolic improvement after 12 weeks of NR in obese, insulin-resistant men, while Yoshino and colleagues, Science 2021, reported improved muscle insulin sensitivity after 10 weeks of NMN in postmenopausal women with prediabetes. The NADPARK trial, Cell Metabolism 2022, reported higher brain NAD on spectroscopy after 30 days of NR in newly diagnosed Parkinson's patients, with mild clinical change. The pattern: precursors reliably raise blood NAD+; functional effects are small, inconsistent, and confined to selected groups.

For NAD+ given by nose, none. There are no randomised controlled trials of intranasal NAD+ in humans, and no published human pharmacokinetic study showing whether, how much, or how quickly nasal NAD+ enters the blood or the brain. The only human study of NAD+ given directly by any route is the 2019 intravenous pilot in Frontiers in Aging Neuroscience by Grant and colleagues, in which a six-hour infusion produced no rise in plasma NAD+ for the first two hours, consistent with the molecule being broken down as fast as it arrived. It tested no clinical outcome.

• It does not establish that a nasal NAD+ spray raises NAD+ in human blood, brain or any other tissue, or how it compares with the injection. No head-to-head study exists.
• It does not establish an effect on fatigue, cognition, sleep, longevity or any ageing marker from nasal NAD+. Where those endpoints were tested in people, the molecule was an oral precursor.
• It does not establish efficacy for any condition as an approved treatment. NAD+ is not approved for anything, by any route.

Nicotinamide adenine dinucleotide (NAD) is listed in Category 1 — "Bulk Drug Substances Under Evaluation" — of the FDA's list of substances nominated for the 503A bulks list, in the version updated 14 May 2026. The entry carries no route qualifier, so the same listing covers a nasal solution and an injection. Under the FDA's interim policy the agency does not intend to take action against a compounder using a Category 1 substance while its evaluation is pending, provided the conditions in the guidance are met. That is the basis on which a 503A pharmacy compounds NAD+ today.

The nomination the FDA evaluated was for fatigue in multiple sclerosis. Its reviewers found the molecule well characterised but degrading substantially with light, moisture, alkaline pH and room temperature, found the safety data inadequate, and identified no published studies supporting the nominated use. On 8 May 2017 the Pharmacy Compounding Advisory Committee voted not to include NAD on the list, and a proposed rule published 5 September 2019 would not place NAD on the 503A Bulks List. That rule has not been finalised for NAD as of September 2026, so the substance stays in Category 1 and compoundable under the interim policy.

On 15 April 2026 the FDA removed twelve peptides from Category 2, and on 23–24 July 2026 the advisory committee reviewed seven of them. NAD+ was never in Category 2 and was not on the July agenda. Separately, on 30 October 2024 the FDA reminded compounders that food-grade NAD+ powder is not suitable for sterile injectable compounding, after adverse-event reports consistent with endotoxin contamination in intravenous products. That concerned injectables and ingredient sourcing, not NAD+ as a molecule; Pepti's sourcing and testing is on the quality page.

So the accurate description today is: nominated, under FDA evaluation, compoundable under the interim policy, with a 2019 proposal not to list it still open. It is not an FDA-approved drug product, and compounded medications never are.

Most of what people notice early is the spray itself: a cool or slightly bitter drip at the back of the throat, occasional sneezing, dryness. The flushing and chest tightness that go with an NAD+ injection are not reported with the spray. Some notice nothing at all, which says nothing about the course.

If anyone reports a subjective change — usually in how tiring ordinary days feel, or in sleep — prescribers describe it in this window. It is also the window in which placebo effects appear, and there is no controlled human data on nasal NAD+ to separate the two.

NAD+ has no receptor to downregulate and no feedback loop to suppress, so nothing in the literature describes withdrawal or rebound. The body keeps making its own NAD+ at whatever rate it did before.

One actuation in each nostril is 0.2 mL in total, which at 12 mg/mL is 2.4 mg of NAD+ per dose and 4.8 mg a day. The reviewed injection dose is 0.83 mL of a 100 mg/mL solution, 83 mg three times a week. Before any question of absorption, the spray delivers a small fraction of the injection's weekly milligrams. That is a design choice — frequent, low, needle-free — not an equivalence.

Because clearance is fast, how the spray lands matters. Blow the nose gently first. Tilt the head slightly forward, aim the nozzle away from the septum toward the outer wall of the nostril, spray while breathing in gently, and do not sniff hard afterwards — a hard sniff pulls the dose straight to the throat. Prime the pump as the pharmacy's leaflet directs if it has sat unused.

The bottle holds 125 doses of 0.2 mL. Used twice daily that is roughly nine weeks, so unlike the injection vials, which are cut to a 28-day cycle, the nasal spray is refilled on the bottle rather than on the calendar, inside its beyond-use date. One bottle per fill, always.

Refrigerated, and it ships that way in insulated packaging with ice packs. Storage matters more than usual: the FDA's own review describes NAD+ degrading with heat, moisture, alkaline pH and light. Keep it in the fridge, out of light, cap on, and follow the beyond-use date on the label, which runs from first use.

Same molecule, different exposure. The NAD+ Injection delivers 83 mg subcutaneously three times a week. The spray delivers 2.4 mg to the nasal lining twice a day, where an unknown share crosses and the rest is swallowed. The injection has the flushing reaction and the needle; the spray has neither, and nasal irritation instead. There is no published human comparison between the two. Where a physician wants the larger systemic dose, the injection is the tool; where the person will not inject, the spray is how NAD+ gets used at all.

The 500 mg injection is the injection at half the vial strength, which a physician may choose for a first course by needle. It is still an injection with the injection's reaction profile; the choice between it and the spray is about route first and dose second.

The precursors have the randomised human trials; the spray does not. The precursors go through the gut and are converted; the spray applies NAD+ itself to a membrane. Someone who wants the most human evidence for raising blood NAD+ wants an oral precursor. Someone who wants NAD+ itself without a needle has the spray as the only prescription format that offers it.